Anti-PPAT Polyclonal Antibody for WB, IF/ICC, ELISA - Q06203

Core Product Specifications and Parameters

Biological Background: PPAT Function and Localization

• PPAT, also known as glutamine phosphoribosylpyrophosphate amidotransferase (GPAT), is the enzyme responsible for catalyzing the first committed step of de novo purine biosynthesis.
• It converts phosphoribosylpyrophosphate (PRPP) and glutamine into phosphoribosylamine, a critical precursor for purine nucleotide synthesis.
• The enzyme contains a 4Fe-4S iron-sulfur cluster and requires magnesium as a cofactor for catalytic activity.
• PPAT is subject to allosteric regulation and post-translational acetylation, which modulate its activity in response to cellular nucleotide demands.
• Its ubiquitous expression pattern reflects the housekeeping role of purine biosynthesis in all tissues.
• With a molecular weight of approximately 57 kDa (57.4 kDa predicted from sequence), PPAT is a common target in proteomic studies.

Experimental Guidance and Technical Tips

• For Western blotting, a recommended starting dilution range is 1:500 to 1:2000; optimization is essential to achieve specific and clear signals.
• Positive control lysates can be prepared from widely available cell lines (e.g., HeLa, HEK293) or mouse/rat tissues, given the ubiquitous expression of PPAT.
• In immunofluorescence/ICC, proper fixation and permeabilization protocols should be tested to ensure antibody accessibility to the target.
• When using for ELISA, consider pairing with a matched detection antibody and validate in the relevant sample matrix.
• Cross-reactivity with mouse and rat PPAT has been observed; however, individual validation in the specific experimental system is recommended.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides diagnostic manufacturers and research laboratories with streamlined access to high-quality IVD raw materials. This anti-PPAT polyclonal antibody is part of our comprehensive portfolio for nucleotide metabolism research, and we offer additional support such as validated antibody pairs, optimized monoclonal/polyclonal antibodies, bulk ancillary reagents, and rare-target raw-material sourcing to accelerate your assay development from concept to clinic.